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Abstract: Natural killer (NK) cells are suitable targets for cancer immunotherapy owing to their
potent cytotoxic activity. To maximize the therapeutic efficacy of cancer immunotherapy, adjuvants
need to be identified. Resveratrol is a well-studied polyphenol with various potential health benefits,
including antitumor effects. We previously found that resveratrol is an NK cell booster, suggesting
that it can serve as an adjuvant for cancer immunotherapy. However, the molecular mechanism
underlying the activation of NK cells by resveratrol remains unclear. The present study aimed to
determine this mechanism. To this end, we investigated relevant pathways in NK cells using Western
blot, real-time polymerase chain reaction, pathway inhibitor, protein/DNA array, and cytotoxicity
analyses. We confirmed the synergistic effects of resveratrol and interleukin (IL)-2 on enhancing the
cytolytic activity of NK cells. Resveratrol activated Akt by regulating Mammalian Target of Rapamycin
(mTOR) Complex 2 (mTORC2) via phosphatase and tensin homolog (PTEN) and ribosomal protein
S6 kinase beta-1 (S6K1). Moreover, resveratrol-mediated NK cell activation was more dependent
on the mTOR pathway than the Akt pathway. Importantly, resveratrol increased the expression of
c-Myb, a downstream transcription factor of Akt and mTORC2. Moreover, c-Myb was essential
for resveratrol-induced NK cell activation in combination with IL-2. Our results demonstrate that
resveratrol activates NK cells through Akt- and mTORC2-mediated c-Myb upregulation.
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1. Introduction
Natural killer (NK) cells are innate immune lymphocytes that play a key role in the first line of
defense against pathogens and cancer [1]. As the name suggests, NK cells spontaneously kill target
cells, such as cancer and virus-infected cells, without presensitization [2]. In addition, NK cells have
the potential to regulate T cell responses by secreting cytokines and activating dendritic cells [3].
Naïve NK cells can be activated by various proinflammatory cytokines, such as interleukin (IL)-2, IL-12,
and IL-15 [4,5]. These cytokines stimulate NK cell proliferation and enhance NK cell cytotoxicity and
have been used in clinical studies to activate NK cells, such as in IL-2 therapy [6]. However, a high-dose
IL-2 therapy can lead to severe adverse effects, including vascular leakage and organ injury caused by
the activation of the vascular endothelium [6,7].
Cancer immunotherapy is a type of therapy that boosts the natural immune system of the body to
fight cancer [8–11]. Most immunotherapeutic strategies have mainly focused on T cell responses, but recent
studies have attempted to use NK cells as potential therapeutic targets in cancer therapy [12–15].
Despite major breakthroughs, clinical studies have exposed the limitations associated with using NK
cells, such as their low treatment efficacy and response rate and resistance to immunotherapies [16–18].
To overcome these limitations, researchers are actively searching for new drug candidates that can
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boost the therapeutic efficacy of cancer immunotherapy [19–22]. Food nutrients, such as resveratrol,
curcumin, and pomegranate, are intriguing sources of therapeutic adjuvants for cancer prevention and
treatment because they have relatively favorable safety profiles and have shown promising efficacy for
combating tumor cells [23,24].
Resveratrol is a well-studied polyphenol, which has been shown to possess various beneficial
properties, including antitumor, anti-inflammatory, antiviral, antifungal, and antibacterial effects [25].
The antitumor effects of resveratrol have been demonstrated in several studies [26]. Interestingly,
several studies have reported the synergistic antitumor effect of resveratrol and doxorubicin on different
breast and colon cancer cell lines [27,28]. Prior studies have also demonstrated that resveratrol exerts
simultaneous effects on NK and T cells [29]. In a previous study, we showed that resveratrol contributes
to enhanced NK cell cytotoxicity in vitro and in vivo, suggesting that resveratrol could be used as
an adjuvant for cancer immunotherapy [30]. However, the molecular mechanism through which
resveratrol activates NK cells remains unclear. Therefore, in this study, we aimed to elucidate the
mechanism of NK cell activation by resveratrol.
2. Results
2.1. Synergistic Effect of Resveratrol and IL-2 on NK Cell Activation
IL-2, IL-12, and IL-15 are known to induce interferon (IFN)-γ secretion and play an important
role in the activation of NK cells [4,5]. In a previous study, we showed that resveratrol activates NK
cells in a synergistic manner with IL-2 [30]. To identify whether resveratrol has synergistic effects with
other cytokines that mediate NK cell activation, we first measured IFN-γ secretion and NK cytotoxicity
following treatment with resveratrol and IL-2, IL-12, or IL-15. Among these cytokines, IL-2 produced
the highest level of IFN-γ secretion at the same concentration compared to other cytokines when they
were added to cells in combination with resveratrol (Figure 1a). In addition, we found that resveratrol
treatment in combination with 5 ng/mL IL-2 was as effective as treatment with 10 ng/mL of IL-2
alone (Figure 1a). We next investigated whether resveratrol has synergistic effects with the activating
cytokines on NK cell cytotoxicity. As shown in Figure 1b, only the combination of resveratrol and
IL-2 showed synergistic effects on the enhancement of the cytolytic activity of NK cells. These results
suggest that resveratrol may activate a factor downstream of the IL-2 signaling pathway.
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Figure 1. Synergistic effect of resveratrol and interleukin (IL)-2 on natural killer (NK) cell activation. 
Fresh medium was used without IL-2 for the experiments with IL-12 or IL-15. (a) Interferon (IFN)-γ 
secretion in NK92 cells after the indicated treatments at various concentrations for 48 h determined 
using an enzyme-linked immunosorbent assay. Data are shown as the mean ± SEM of two 
independent experiments. (b) NK cell cytotoxicity was determined using the calcein-AM assay. NK92 
effector cells were treated with each cytokine (IL-2, 5 ng/mL; IL-12 and IL-15, 10 ng/mL) with or 
Figure 1. Synergistic effect of resveratrol and interleukin (IL)-2 on natural killer (NK) cell activation.
Fresh medium was used without IL-2 for the experiments with IL-12 or IL-15. (a) Interferon (IFN)-γ
secretion in NK92 cells after the indicated treatments at various concentrations for 48 h determined
using an enzyme-linked immunosorbent assay. Data are shown as the mean ± SEM of two independent
exper ments. (b) NK cell cytotoxicity was determined using th calcein-AM assay. NK92 effector cells
were treated with each cytokine (IL-2, 5 ng/mL; IL-12 and IL-15, 10 ng/mL) with or without 20 µM
resveratrol for 36 h, followed by incubation with K562 target cells at a 1:1 ratio for 4 h. Data are shown
as the mean ± SEM of three independent experiments. Asterisks indicate statistical significance using
one-way ANOVA: * p < 0.05, ** p < 0.01, *** p < 0.001, ns: not significant (p > 0.05).
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2.2. Regulation of the Akt and Mammalian Target of Rapamycin (mTOR) Complex 2 (mTORC2) Signaling
Pathway by Resveratrol
IL-2 signaling is propagated following receptor–ligand engagement, controlling the recruitment
of Janus kinases 3 (JAK3) and activation of Akt, extracellular signal-regulated kinase (ERK) 1/2,
and transcriptionally active signal transducer and activator of transcription 5 (STAT5) [31,32].
Thus, we investigated which molecule(s) is regulated by resveratrol among these IL-2 signaling-mediated
proteins. As shown in Figure 2, we found that resveratrol increased the phosphorylation of Akt, but it
had no effect on the phosphorylation of Stat5 and ERK. These results suggest that resveratrol activates
the Akt signaling pathway but not the Stat5 and ERK signaling pathways.
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expression and total form. Data are shown as the mean ± SEM of three independent experiments. 
Asterisks indicate statistical significance using one-way ANOVA: ** p < 0.01, ns: not significant (p > 
0.05). 
Next, to determine the mechanism through which resveratrol activates Akt, we measured the 
expression levels of phosphoinositide-dependent kinase-1 (PDK1) and mTORC2, which are upstream 
of Akt [33]. As shown in Figure 3a, PDK1 expression was not affected by resveratrol, whereas the 
level of phospho-rictor (a subunit of mTORC2) decreased significantly. Previous studies have shown 
that phosphorylated rictor negatively regulates mTORC2 expression as part of a negative feedback 
mechanism controlling Akt activity [34]. Consistent with this, resveratrol also appeared to inhibit 
phosphatase and tensin homolog (PTEN) and ribosomal protein S6 kinase beta-1 (S6K1) activities, 
which are known to downregulate mTORC2 signaling (Figure 3b). Collectively, our data suggest that 
resveratrol activates Akt by regulating rictor phosphorylation and mTORC2 via PTEN and S6K1. 
Fig re 2. Regulation of the Akt signaling pathway by resveratrol. NK92 cells were deprived of interleukin
(IL)-2 for 24 h and then treated with IL-2 (5 ng/mL) with or without 20 µM resveratrol for 30 min. Western
blot showing (a) Stat5 (pTyr694), (b) Erk (pThr202/Tyr204), and (c) Akt (pSer473) expression and total
form. Data are shown as the mean ± SEM of three independent experiments. Asterisks indicate statistical
significance using one-way ANOVA: ** p < 0.01, ns: not significant (p > 0.05).
Next, to determine the mechanism through which resveratrol activates Akt, we measured the
expression levels of phosphoinositide-dependent kinase-1 (PDK1) and mTORC2, which are upstream
of Akt [33]. As shown in Figure 3a, PDK1 expression was not affected by resveratrol, whereas the
level of phospho-rictor (a subunit of mTORC2) decreased significantly. Previous studies have shown
that phosphorylated rictor negatively regulates mTORC2 expression as part of a negative feedback
mechanism controlling Akt activity [34]. Consistent with this, resveratrol also appeared to inhibit
phosphatase and tensin homolog (PTEN) and ribosomal protein S6 kinase beta-1 (S6K1) activities,
which are known to downregulate mTORC2 signaling (Figure 3b). Collectively, our data suggest that
resveratrol activates Akt by regulating rictor phosphorylation and mTORC2 via PTEN and S6K1.
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Figure 3. Regulation of the mammalian target of rapamycin (mTOR) complex 2 signaling pathway by
resveratrol. NK92 cells were deprived of interleukin (IL)-2 for 24 h and then treated with IL-2 (5 ng/mL)
with or without 20 µM resveratrol for 30 min. (a) Western blot showing phosphoinositide-dependent
kinase-1 (PDK1) (pSer241) and rictor (pThr1135) expression and total form. Data are shown as the
mean ± SEM of four independent experiments. (b) Western blot showing phosphatase and tensin
homolog (PTEN) and ribosomal protein S6 kinase beta-1 (S6K1) (pThr389) expression and total form.
Data are shown as the mean ± SEM of three independent experiments. Asterisks indicate statistical
significance using the Student’s t-test: * p < 0.05, ** p < 0.01, *** p < 0.001, ns: not significant (p > 0.05).
2.3. Effects of Akt and mTORC2 on Resveratrol-Induced NK Cell Activation
We investigate whether NK cell activation is the direct effect of resveratrol-induced Akt and
mTORC2 activation. For this purpose, IFN-γ secretion and NK cell cytotoxicity were measured after
treatment with the Akt inhibitor MK-2206 (Figure 4a). As shown in Figure 4a, the Akt inhibitor
decreased IFN-γ secretion and NK cell cytotoxicity, but the inhibition was to a substantial extent
overcome by resveratrol treatment. These results suggest that resveratrol may also activate NK
cells in a manner other than the Akt signaling pathway. We next compared IFN-γ secretion and
NK cell cytotoxicity after treatment with the mTOR inhibitor KU-0063794 (Figure 4b). As shown in
Figure 4b, the mTOR inhibitor decreased IFN-γ secretion and NK cell cytotoxicity, but the inhibition
was only slightly overcome by resveratrol treatment. Interestingly, the mTOR inhibitor decreased
resveratrol-induced NK cell activation ore than the Akt inhibitor (Figure 4a,b). These results suggest
that resveratrol-mediated NK cell activation is more dependent on the mTOR pathway than the
Akt pathway.
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5a, the activities of 56 transcription factors in NK cells were screened using this method. To select 
candidates whose activity increased following resveratrol treatment, we first excluded candidates 
with a spot density lower than 4000. Next, we selected transcription factors with a higher than 2-fold 
increase in spot density induced by resveratrol compared with treatment with IL-2 alone (Figure 5a). 
Consequently, we identified four transcription factors (CBF, c-Myb, NF-E2, and SP-1) and found that 
they were all related to the Akt signaling pathway [35–38]. Resveratrol is known to upregulate NF-
E2 expression, and we previously reported that c-Myb is a key factor involved in the regulation of 
Figure 4. Effects of Akt and mammalian target of rapamycin (mTOR) complex 2 (mTORC2) on natural
killer (NK) cell activation by resveratrol. Interferon (IFN)-γ secretion in NK92 cells after the indicated
treatments for 48 h determined using an enzyme-linked immunosorbent assay. NK cell cytotoxicity was
determined using the calcein-AM assay. NK92 effector cells were harvested after the indicated treatments
for 36 h, followed by incubation with K562 target cells at a 1:1 ratio for 4 h. (a) An Akt in ibitor (MK-2206)
was added 30 min before resveratrol treatment. (b) An mTOR inhibitor KU-0063794) was added 30 min
before resveratrol treatment. Results ar presented s mean ± SD of triplicat measurements. Three
independent experiments were performed. Asterisks indicate statistical significance using one-way
ANOVA: * p < 0.05, ** p < 0.01, *** p < 0.001, ns: not significant (p > 0.05).
2.4. Upregulation of Akt-Related Transcription Factors in NK Cells by Resveratrol
Next, we performed a high-throughput analysis of transcription factor activation using a protein/DNA
array to identify the transcription factors activated by resveratrol. As shown in Figure 5a, the activities of
56 transcription factors in NK cells were screened using this method. To select candidates whose activity
increased following resveratrol treatment, we first excluded candidates with a spot density lower than
4000. Next, we selected transcription factors ith a higher than 2-fold increase in spot density induced
by resver trol compared with treatm nt with IL-2 alone (Figure 5a). Consequently, we identified
four tra scription factors (CBF, c-Myb, NF-E2, and SP-1) and found that they were all related to
the Akt signaling pathway [35–38]. Resveratrol is known to upregulate NF-E2 ex ression, and we
previously reported that c-Myb is a key factor involved in the regulation of NK cell activity [39,40].
In this study, we further investigated the effect of resveratrol on the expression of c-Myb. As shown in
Figure 5b,c, IL-2 appeared to increase the mRNA and protein expression levels of c-Myb. As expected,
resveratrol significantly increased the level of c-Myb expression compared with that induced by
Int. J. Mol. Sci. 2020, 21, 9575 6 of 13
IL-2 treatment alone. Next, we investigated whether resveratrol-induced c-Myb activation was
dependent on the Akt and mTOR pathways. As shown in Figure 5d, the Akt inhibitor decreased c-Myb
expression, but the inhibition was overcome by resveratrol treatment. Furthermore, the mTOR inhibitor
decreased c-Myb expression, but the inhibition was not completely overcome by resveratrol treatment.
Altogether, these results suggest that the mTOR pathway is more important in resveratrol-induced
c-Myb upregulation than the Akt pathway.
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Data are shown as the mean ± SEM of three independent experiments. (d) Western blot showing c-
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2.5. Effects of c-Myb on Resveratrol-Induced NK Cell Activation 
Figure 5. Upregulation of Akt-related transcription factors in natural killer (NK) cells by resveratrol.
(a) NK92 cells were deprived of interleukin (IL)-2 for 24 h and then treated with IL-2 (5 ng/mL) with or
without 20 µM resveratrol for 30 min. Data are shown as the mean ± SD of duplicate measurements.
(b) The mRNA levels of c-Myb in NK92 cells after resveratrol treatment for 24 h measured using real-time
polymerase chain reaction and calculated using the ∆∆CT method. Glyceraldehyde 3-phosphate
dehydrogenase (Gapdh) was used as an internal control. (c) Western blot showing c-Myb expression.
Data are shown as the mean ± SEM of three independent experiments. (d) Western blot showing c-Myb
expression after treatment with the Akt inhibitor (MK-2206) and mammalian target of rapamycin
(mTOR) inhibitor (KU-0063794). Data are shown as the mean ± SEM of three independent experiments.
Asterisks indicate statistical significance using one-way ANOVA: * p < 0.05, *** p < 0.001, ns: not
significant (p > 0.05).
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2.5. Effects of c-Myb on Resveratrol-Induced NK Cell Activation
Finally, we comprehensively investigated the extent to which resveratrol is dependent on c-Myb to
activate NK cells. To identify whether the c-Myb binding site exists within the IFN-γ promoter region,
we used the evolutionary conservation of genomes (ECR) browser, a tool for visualizing and accessing data
from comparisons of multiple vertebrate genomes. As shown in Figure 6a, it was predicted that the c-Myb
binding site exists within the IFN-γ promoter region. Next, we measured the levels of IFN-γ (Figure 6b)
and cytolytic activity (Figure 6c) after treatment with the c-Myb inhibitor, celastrol, to investigate whether
resveratrol depends on c-Myb to activate NK cells. As shown in Figure 6b,c, the effects of resveratrol were
completely abrogated upon celastrol-induced c-Myb inhibition. We further confirmed that resveratrol
action depends on c-Myb by performing c-Myb knockdown studies in NK cells. As shown in Figure 6d,
the effects of resveratrol were completely abrogated by using a c-Myb shRNA in the NK92 cell line.
Altogether, these results indicate that resveratrol-induced activation of NK cells is dependent on c-Myb.
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Figure 6. Effects of c-Myb on natural killer (NK) cell activation induced by resveratrol. (a) Annotation of
conserved transcription factor binding sites underlying the evolutionary conservation of genomes (ECR)
browser conservation plots displayed using the “Synteny/Alignments” link in the top menu. (b,c) The c-Myb
inhibitor, celastrol, was added 30 min before resveratrol treatment. (b) Interferon (IFN)-γ secretion in NK92
cells after the indicated treatments for 36 h determined using an enzyme-linked immunosorbent assay.
Results are presented as mean ± SD of quadruplicate measurements. Three in ependent experiments were
performed. (c,d) NK c ll cytotoxicity was deter ined using th calcein-AM assay. NK92 eff ctor cells were
harvested after the indicated treatment for 36 h, followed by incubation with K562 target cells at a 1:1 ratio
for 4 h. Data are shown as the mean ± SEM of six independent exp riments. Asterisks i dicate statistical
sig ificance using one-way ANOVA: *** p < 0.001, n : not significant (p > 0.05).
3. Discussion
NK cells are endowed with potent cytolytic activity against tumors, and the efficacy of NK
cell-mediat d immun th rapy can be enhan ed by immune stimulants, such as cytokines and
antibodi s [4]. In this study, we found that resveratrol showed a synergistic effect in combination
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with IL-2, IL-12, and IL-15 on IFN-γ secretion; however, a synergistic effect on the cytolytic activity
of NK cells was only observed in combination with IL-2 (Figure 1). Additionally, we demonstrated
that resveratrol activates Akt by regulating mTORC2 via PTEN and S6K1 (Figures 2 and 3). Moreover,
we found that resveratrol-mediated NK cell activation was more dependent on the mTOR pathway
than the Akt pathway, and resveratrol upregulated the expression of c-Myb, a key regulator of NK
cell activity (Figures 4–6). mTORC2 directly activates PKC and SGK; SGK gene family members are
known to be similar to those of the MYB gene family [41]. Interestingly, SGK1 is known to regulate Th1
and Th2 differentiation downstream of mTORC2 [42]. Therefore, it would be interesting to confirm
whether mTORC2 can also directly activate c-Myb, as in the case of SGK1.
MicroRNAs (miRNAs) are a highly conserved class of small noncoding RNAs with important
regulatory functions in cell proliferation, differentiation, signal transduction, immune response,
and carcinogenesis [43,44]. miR-155 enhances IFN-γ production in NK cells, and it is upregulated
by the transcription factor c-Myb [45,46]. miR-150 is widely expressed in immune cells and plays
an important role in the development of lymphocytes and hematopoietic malignancies [47]. Several
studies have reported that miR-150 negatively regulates CD8 T cell memory formation and controls B
cell differentiation by targeting c-Myb [48,49]. In this study, we found that resveratrol activates NK
cells by upregulating the expression of c-Myb (Figure 6). Thus, it would be informative to investigate
whether resveratrol activates NK cells by stimulating miR-155 function as a result of upregulating
c-Myb expression or by inhibiting miR-150 function.
Tumor progression usually leads to NK cell exhaustion, thus limiting the antitumor potential
of NK cells [50]. Tim-3 is involved in T cell exhaustion. Interestingly, Tim-3 is also expressed in NK
cells [51]. Tim-3 expression in NK cells increases as the melanoma stage progresses [51]. Furthermore,
Tim-3 blockade reverses the exhausted phenotype of NK cells [51]. These data may lead to the
development of new therapies targeting Tim-3 in tumor immunotherapy. We previously reported
that IFN-γ secretion decreased in NK cells collected from tumor-bearing mice. This phenomenon
could have occurred because those NK cells were already activated in vivo, and at the time of sample
collection, they were in an exhaustion phase. Furthermore, we observed that resveratrol increases
IFN-γ secretion even in NK cells from tumor-bearing mice, suggesting that resveratrol reverses NK
cell exhaustion and overcomes the exhaustion-related decreased antitumor potential of NK cells. Thus,
it would be worthy to investigate if resveratrol blocks Tim-3 or other exhaustion markers in NK cells
from tumor-bearing mice.
Our findings demonstrated that resveratrol enhances NK cell activity by increasing the expression
of c-Myb (Figure 6). c-Myb is already known to enhance the function of CD8+ T and NK cells. Hence,
resveratrol could serve as a potential adjuvant for cancer immunotherapy, since it enhances the CD8+
T cell response and NK cell activity.
4. Materials and Methods
4.1. Cell Lines and Cell Culture
All cell lines were obtained from ATCC (Manassas, VA, USA). The human NK cell line, NK92,
was maintained in minimum essential medium α (Gibco, New York, NY, USA) supplemented
with 12.5% heat-inactivated fetal bovine serum (FBS; Gibco), 12.5% heat-inactivated horse serum
(Gibco), 0.2 mM myo-inositol (Sigma-Aldrich, St. Louis, MO, USA), 0.1 mM 2-mercaptoethanol
(Sigma-Aldrich), 0.02 mM folic acid (Sigma-Aldrich), 1% penicillin/streptomycin (WelGENE,
Gyeongsansi, Korea), and 5 ng/mL IL-2 (ATGen, Sungnamsi, Korea). The human erythroleukemia
cell line, K562, was maintained in RPMI 1640 medium (Gibco) supplemented with 10% FBS and 1%
penicillin/streptomycin.
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4.2. Antibodies and Reagents
Resveratrol, anti-β-actin antibody, and the c-Myb inhibitor, celastrol, were purchased from
Sigma-Aldrich. For Western blotting, monoclonal antibodies against phospho-STAT5, STAT5,
phospho-Akt, Akt, phospho-Erk, Erk, phospho-PDK1, PDK1, phospho-rictor, rictor, and c-Myb
were purchased from Cell Signaling Technology (Danvers, MA, USA).
4.3. Enzyme-Linked Immunosorbent Assay (ELISA)
An IFN-γ ELISA set was purchased from BD Biosciences (San Diego, CA, USA). NK92 cells
(5 × 104 cells/well) were dispensed in a 24-well plate and incubated for 36 h. Then, the supernatants
were harvested and dispensed in triplicate into a 96-well microplate pre-coated with the capture
antibody. After incubation for 2 h, each well was washed with washing buffer (0.05% Tween 20 in PBS,
pH 7.4), followed by incubation with the HRP-conjugated detection antibody for 1 h. The substrate
solution 3,3′,5,5′-tetramethylbenzidine was added to the wells in the dark. Absorbance was measured
at 450 nm using a microplate reader (Epoch, BioTek, Winooski, VT, USA).
4.4. Cytotoxicity Assay
The calcein-AM (Invitrogen, Carlsbad, CA, USA) assay was used to measure NK cell cytotoxicity
against target cells. Calcein-AM was added to target cells at a final concentration of 2 µM and incubated
for 30 min at 37 ◦C and 5% CO2. The calcein-AM-labeled target cells were washed with PBS twice,
following which 1 × 104 cells were dispensed in quadruplicate into a 96-well round-bottom plate.
NK cells were added at different effector:target ratios and co-cultured for 4 h. The amount of calcein-AM
released from the lysed target cells was measured using a spectrophotometer (ex: 485 nm/em: 535 nm).
Total specific lysis was calculated using the following formula:
Specific cytotoxicity (%)=
Experimental release− spontaneous release
Maximum release− spontaneous release
× 100
4.5. Western Blot Analysis
After treatment, NK92 cells were harvested and washed. The cells were lysed in RIPA buffer
supplemented with a protease and phosphatase inhibitor cocktail. Protein concentration was determined
using the bicinchoninic acid (BCA) protein assay (Thermo Scientific, Seoul, Korea). Sample buffer
was added to each sample, following which the samples were boiled at 100 ◦C for 5 min, cooled on
ice, and loaded onto a 10% sodium dodecyl sulfate (SDS)-polyacrylamide gel. After electrophoresis,
the proteins were transferred onto a methanol-activated polyvinylidene fluoride (PVDF) membrane,
which was blocked with 5% skim milk to prevent nonspecific reactivity. The membrane was probed with
specific antibodies diluted in Tris Buffered Saline (TBS)-T containing 3% bovine serum albumin (BSA)
and incubated overnight at 4 ◦C. The membrane was washed three times for 10 min each and incubated
for 1 h with the secondary antibodies. Immunoreactivity was detected using an ECL solution (Thermo
Scientific, Seoul, Korea).
4.6. Protein/DNA Array for Transcription Factors
The nuclear extracts from NK92 cells were prepared using the nuclear extraction kit (Panomics,
Fremont, CA, USA) following the manufacturer’s instructions. A total of 5 µg of nuclear extracts were
mixed with the DNA probe (10 ng/µL). Each array was performed following the procedure in the
Protein/DNA Array kit (Panomics) user manual. The membrane was detected using chemiluminescent
reagents and exposed to photographic film. The array images were acquired, and the spot intensities
of all the detected transcription factors were measured using Image J software (java version, NIH).
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4.7. Real-Time Polymerase Chain Reaction (PCR) Analysis
Total RNA was extracted from NK92 cells using TRIzol (Life Technologies, Carlsbad, CA, USA),
and cDNA was synthesized using the SensiFAST cDNA synthesis kit (Bioline, Taunton, MA, USA)
according to the manufacturer’s instructions. The synthesized cDNAs were used as templates for
subsequent PCR amplification of the c-Myb and GAPDH genes. The following primers were used:
c-Myb, 5′-CATGTTCCATACCCTGTAGCG-3′ and 5′-TTCTCGGTTGACATTAGGAGC-3′;
GAPDH, 5′-CAGCCTCAAGATCATCAGCA-3′ and 5′-GTCTTCTGGGTGGCAGTGAT-3′.
Real-time PCR was carried out using the KAPA SYBR FAST qPCR kit (KAPA Biosystems,
Wilmington, MA, USA), and amplification was performed on an ABI Prism StepOnePlusTM detection
system (Applied Biosystems, Foster City, CA, USA) according to the conditions recommended by
the manufacturer. The experiments were performed in triplicate, and results were normalized to the
expression of GAPDH. The relative expression levels of the target genes were calculated using the
2−∆∆Ct method.
4.8. ECR Browser
To identify whether the c-Myb binding site exists within the IFN-γ promoter region, we used
the ECR browser, a tool for visualizing and accessing data from comparisons of multiple vertebrate
genomes. Annotations of the conserved transcription factor binding sites underlying the ECR Browser
conservation plots were displayed using the “Synteny/Alignments” link in the top menu and performed
following the procedure provided in the instructions.
4.9. c-Myb Knockdown Using Lentiviral Transduction
The MYB shRNA and control shRNA plasmids were purchased from Sigma-Aldrich. Lentiviral
particles were produced using a third-generation packaging system. For this system, pMDLg/pRRE
(plasmid #12251; Addgene, Cambridge, MA, USA), pRSV-Rev (plasmid #12253; Addgene), and pMD2.G
(plasmid #12259; Addgene) were kindly provided by Dr. Didier Trono. To transfect the plasmids
into HEK293T cells, Lipofectamine 3000 was used (Invitrogen). For lentiviral transduction, NK-92
cells were stimulated with IL-2 (5 ng/mL) for 1 h and then infected by mixing with the supernatants
containing the lentiviral particles and protamine sulfate (15 µg/mL; Sigma Aldrich, Seoul, Korea).
To increase lentiviral transduction efficiency, the mixtures were centrifuged at 360× g for 90 min at
32 ◦C. For the selection of transgene-positive cells, the cells were cultured in complete growth medium
containing 2 µg/mL puromycin for up to 4 weeks.
4.10. Statistical Analysis
Statistical analysis was performed using the GraphPad Prism software (GraphPad software,
San Diego, CA, USA). Data are expressed as the mean± standard error of the mean (SEM). The student’s
t-test and one- or two-way ANOVA were used to compare distributions between groups. p < 0.05 was
considered statistically significant.
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Abbreviations
BCA Bicinchoninic acid
BSA Bovine serum albumin
ECR Evolutionary conservation of genomes
ELISA Enzyme-linked immunosorbent assay
ERK Extracellular signal regulated kinase




mTOR Mammalian target of rapamycin
mTORC2 Mammalian target of rapamycin complex 2
NK Natural killer
PCR Polymerase chain reaction
PDK1 Phosphoinositide-dependent kinase-1
PTEN Phosphatase and tensin homolog
PVDF Polyvinylidene fluoride
STAT5 Signal transducer and activator of transcription 5
S6K1 Ribosomal protein S6 kinase beta-1
SDS Sodium dodecyl sulfate
TBS Tris buffered saline
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